Emerging therapies for thyroid carcinoma.

Hdl Handle:
http://hdl.handle.net/10147/207341
Title:
Emerging therapies for thyroid carcinoma.
Authors:
Walsh, S; Prichard, R; Hill, A D K
Affiliation:
Department of Surgery, RCSI Smurfitt Building, Beaumont Hospital, Dublin 9,, Ireland.
Citation:
Surgeon. 2012 Feb;10(1):53-8. Epub 2011 Sep 9.
Journal:
The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland
Issue Date:
1-Feb-2012
URI:
http://hdl.handle.net/10147/207341
DOI:
10.1016/j.surge.2011.08.004
PubMed ID:
22233555
Abstract:
Thyroid carcinoma is the most commonly diagnosed endocrine malignancy. Its incidence is currently rising worldwide. The discovery of genetic mutations associated with the development of thyroid cancer, such as BRAF and RET, has lead to the development of new drugs which target the pathways which they influence. Despite recent advances, the prognosis of anaplastic thyroid carcinoma is still unfavourable. In this review we look at emerging novel therapies for the treatment of well-differentiated and medullary thyroid carcinoma, and advances and future directions in the management of anaplastic thyroid carcinoma.
Language:
eng
ISSN:
1479-666X (Print); 1479-666X (Linking)

Full metadata record

DC FieldValue Language
dc.contributor.authorWalsh, Sen_GB
dc.contributor.authorPrichard, Ren_GB
dc.contributor.authorHill, A D Ken_GB
dc.date.accessioned2012-02-01T10:05:15Z-
dc.date.available2012-02-01T10:05:15Z-
dc.date.issued2012-02-01T10:05:15Z-
dc.identifier.citationSurgeon. 2012 Feb;10(1):53-8. Epub 2011 Sep 9.en_GB
dc.identifier.issn1479-666X (Print)en_GB
dc.identifier.issn1479-666X (Linking)en_GB
dc.identifier.pmid22233555en_GB
dc.identifier.doi10.1016/j.surge.2011.08.004en_GB
dc.identifier.urihttp://hdl.handle.net/10147/207341-
dc.description.abstractThyroid carcinoma is the most commonly diagnosed endocrine malignancy. Its incidence is currently rising worldwide. The discovery of genetic mutations associated with the development of thyroid cancer, such as BRAF and RET, has lead to the development of new drugs which target the pathways which they influence. Despite recent advances, the prognosis of anaplastic thyroid carcinoma is still unfavourable. In this review we look at emerging novel therapies for the treatment of well-differentiated and medullary thyroid carcinoma, and advances and future directions in the management of anaplastic thyroid carcinoma.en_GB
dc.language.isoengen_GB
dc.titleEmerging therapies for thyroid carcinoma.en_GB
dc.contributor.departmentDepartment of Surgery, RCSI Smurfitt Building, Beaumont Hospital, Dublin 9,, Ireland.en_GB
dc.identifier.journalThe surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Irelanden_GB
dc.description.provinceLeinster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.